Alivus Life Sciences has confirmed that operations at its Dahej facility, impacted by a February 14 fire, will resume in phases. API production is set to restart on March 1, 2026, while intermediate manufacturing will recommence by mid-March. Other production blocks remain fully operational.
Alivus Life Sciences Limited, formerly Glenmark Life Sciences, has issued an update regarding the fire incident at its Dahej manufacturing site in Gujarat. The company emphasized that the disruption was limited to one of seven production blocks, with core API facilities unaffected.
Key Highlights
-
The fire was confined to a single production block, impacting intermediate manufacturing facilities
-
API manufacturing units in the same block remain unaffected
-
All six other production blocks at Dahej continue full operations
-
API production at the affected block will resume from March 1, 2026
-
Intermediate production is expected to restart by mid-March 2026
-
Temporary suspension will cause minor shipment delays
-
Company reiterates commitment to stringent safety standards and preventive measures
This phased recovery underscores Alivus Life Sciences’ resilience and operational continuity, ensuring minimal disruption to supply chains while prioritizing safety.
Source: Alivus Life Sciences Limited disclosure to BSE Ltd. and National Stock Exchange of India Ltd.